Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | GLS | O94925 | 6/20 | 0.50 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028409 | 0.87 | CA1 (0.69) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL18546011 | 0.84 | CA1 (0.66) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL10576461 | 0.82 | CA1 (0.67) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL6491441 | 0.82 | CA1 (0.71) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL3453018 | 0.82 | CA1 (0.67) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL29765433 | 0.81 | CA1 (0.65) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL6622747 | 0.79 | CA1 (0.60) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL16248330 | 0.78 | HTR1A (0.63) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL6433592 | 0.77 | KMT2A (0.65) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL694917 | 0.76 | EPHX2 (0.76) | CA1CA2CA5ACA7CA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014788-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014788-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | CCR5, CCR2, CCL2 | CA1 3872/4885CA2 2950/4885CA5A 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.